DUALITYBIO-B(09606),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09606 DUALITYBIO-B

Closed 03-17 16:08:14

296.000

+12.000

+4.23%

High309.800	Low284.600	Vol1.20M
Open284.600	D1 Closing284.000	Amplitude8.87%
Mkt Cap26.68B	Tradable Cap26.68B	Total Shares90.14M
T/O359.08M	T/O Rate1.33%	Tradable Shares90.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"DUALITYBIO-B","latestPrice":296,"timestamp":1773734894007,"preClose":284,"halted":0,"volume":1197252,"delay":0,"changeRate":0.04225352112676056,"floatShares":90137700,"shares":90137700,"eps":-131.30424,"marketStatus":"Closed","change":12,"latestTime":"03-17 16:08:14","open":284.6,"high":309.8,"low":284.6,"amount":359077078,"amplitude":0.088732,"askPrice":296.4,"askSize":400,"bidPrice":296,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-34.438,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773797400000},"marketStatusCode":5,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":284,"openAndCloseTimeList":[[1773711000000,1773720000000],[1773723600000,1773734400000]],"volumeRatio":1.094848,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606","defaultTab":"news","newsList":[{"id":"1156982969","title":"HK Movers | Biotech Stocks Jump. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1156982969","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156982969?lang=en_us&edition=fundamental","pubTime":"2026-03-17 10:41","pubTimestamp":1773715275,"startTime":"0","endTime":"0","summary":"Biotech stocks jumped in Hong Kong. Wuxi XDC up 7%; Junshi Bio up 6%; Remegen, Genscript Bio, Wuxi Apptec up around 5%; Innocare up over 4%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","02269","06606","09688","03759","01672","09995","02137","09966","03347","02268","09606","06978"],"gpt_icon":0},{"id":"1190504580","title":"DUALITYBIO-B (09606) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results and Review Final Dividend Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=1190504580","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190504580?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:43","pubTimestamp":1773218620,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics, Inc. (stock code: 09606, abbreviation: DUALITYBIO-B) has scheduled a board meeting for 23 March 2026. According to the company’s announcement, directors will consider and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":0},{"id":"2618912338","title":"Duality Biotherapeutics to Hold Board Meeting on Annual Results and Final Dividend Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2618912338","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618912338?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:31","pubTimestamp":1773217911,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics will hold a board meeting on March 23, 2026 to consider and approve its annual results for the year ended Dec. 31, 2025. The board will also consider a recommendation on the payment of a final dividend.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL28J91w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","HK0000252152.HKD","09606","BK1161","HK0000252160.HKD","HK0000500386.USD"],"gpt_icon":0},{"id":"1179855228","title":"Prospective Adjustments to Hong Kong Stock Connect in March: 44 Stocks Poised for Inclusion, Featuring Insilico (03696) and JD Industrials (07618)","url":"https://stock-news.laohu8.com/highlight/detail?id=1179855228","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179855228?lang=en_us&edition=fundamental","pubTime":"2026-03-06 14:32","pubTimestamp":1772778725,"startTime":"0","endTime":"0","summary":"According to the quarterly review results announced by Hang Seng Indexes Company on February 13, the adjustments will officially take effect starting March 9 (next Monday). Following the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00023","CTRYY","02788","BK1170","BKEAY","01384","00863","02609","SG9999003461.SGD","00659","BK4585","02656","BK1572","BK1601","BK1207","BK1124","02617","BK1141","NWSGY","BK4588","BK1231","09606","BK1160","BK1175","07618","02698","BK1230","02007","03660","BK1117","03887","QFIN","03696"],"gpt_icon":0},{"id":"1109377962","title":"Duality Biotherapeutics (09606) Announces February 2026 Monthly Return on Securities Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1109377962","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109377962?lang=en_us&edition=fundamental","pubTime":"2026-03-02 16:50","pubTimestamp":1772441419,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics, Inc. reported no changes in its authorized or issued share capital for the month ended 28 February 2026. Authorized share capital remained at 200,000,000 ordinary shares,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":0},{"id":"2613763897","title":"Duality Biotherapeutics Says DB-1311 Shows Signs of Activity in Early-Stage Prostate Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2613763897","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613763897?lang=en_us&edition=fundamental","pubTime":"2026-02-24 11:33","pubTimestamp":1771904032,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics (HKG:9606) said updated data from an early-stage study of DB-1311/BNT324 showed signs of activity in patients with advanced prostate cancer who had already received multiple pr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4552","SSI","LU2543165471.USD","BK4118","BK4566","DB","HK0000500386.USD","09606","BK4585","BK4588","HK0000252152.HKD","BK1161","HK0000252160.HKD"],"gpt_icon":0},{"id":"1140530522","title":"Duality Biotherapeutics, Inc. (9606) Presents DB-1311/BNT324 Study Updates at ASCO GU Cancers Symposium 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1140530522","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140530522?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:23","pubTimestamp":1771885417,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics, Inc. (the “Company”) (Stock Code: 9606) announced updated results from a Phase 1/2 DB-1311-O-1001 study (NCT05914116) of DB-1311/BNT324, an investigational B7H3 antibody drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":0},{"id":"1101379908","title":"DUALITYBIO-B Announces Phase 1/2 Trial Results for DB-1311/BNT324 at 2026 ASCO GU Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=1101379908","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101379908?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:10","pubTimestamp":1771884635,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) has announced that updated efficacy and safety results from the Phase 1/2 DB-1311-O-1001 study (NCT05914116) for its investigational B7H3 antibody-drug conjugate (ADC),...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4118","HK0000500386.USD","BK1161","HK0000252160.HKD","BK4552","09606","BK4588","DB","BK4566","HK0000252152.HKD","LU2543165471.USD"],"gpt_icon":0},{"id":"2613275840","title":"Duality Biotherapeutics to Present Updated DB-1311/BNT324 Phase 1/2 mCRPC Data at ASCO GU 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2613275840","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613275840?lang=en_us&edition=fundamental","pubTime":"2026-02-24 06:03","pubTimestamp":1771884238,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics Inc. announced updated efficacy and safety results from its Phase 1/2 DB-1311-O-1001 study  evaluating DB-1311/BNT324, an investigational B7-H3 antibody-drug conjugate, in heavily pretreated metastatic castration-resistant prostate cancer. The company said the data will be presented at the ASCO Genitourinary Cancers Symposium 2026  and that the study abstract was published on the symposium website on February 23, 2026. As of the September 5, 2025 data cutoff, 104 patients had been treated; among 58 response-evaluable patients, confirmed objective response rate was 34.5% and disease control rate was 87.9%, with median radiographic progression-free survival of 11.3 months in 82 evaluable patients; outcomes were reported as similar in patients with and without prior lutetium-177 PSMA-617 treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL32V5N0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","09606","BK1161"],"gpt_icon":0},{"id":"1118688603","title":"Hong Kong Stock Market Movement | DUALITYBIO-B (09606) Surges Over 6%, Company's 2026 Clinical Data Expected for Dense Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=1118688603","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118688603?lang=en_us&edition=fundamental","pubTime":"2026-01-27 14:30","pubTimestamp":1769495422,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) rose more than 6%. As of the time of writing, the stock was up 6.04%, trading at HKD 340.6, with a turnover of HKD 154 million. On the news front, according to Pharmaceutical...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","09606","BK1161","LU2543165471.USD"],"gpt_icon":0},{"id":"1138834224","title":"Hong Kong Stock Movement | DUALITYBIO-B (09606) Rises Over 4% in Morning Session as ADAM9-Targeting ADC Cancer Drug Approved for Clinical Trials in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1138834224","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138834224?lang=en_us&edition=fundamental","pubTime":"2026-01-20 09:53","pubTimestamp":1768873996,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) saw its shares rise more than 4% during the morning trading session. At the time of writing, the stock was up 2.42%, trading at HKD 363.6, with a turnover of HKD 51.06 million....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","ADC","BK4080","BK1161","HK0000252160.HKD","BK4231","09606","HK0000252152.HKD","LU2543165471.USD"],"gpt_icon":0},{"id":"2604159280","title":"Duality Biotherapeutics Executive Director of Human Resources & Executive Director Wen Si Sells 100% Of Holding","url":"https://stock-news.laohu8.com/highlight/detail?id=2604159280","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604159280?lang=en_us&edition=fundamental","pubTime":"2026-01-20 07:07","pubTimestamp":1768864035,"startTime":"0","endTime":"0","summary":"Some Duality Biotherapeutics, Inc. ( HKG:9606 ) shareholders may be a little concerned to see that the Executive...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9606/duality-biotherapeutics-shares/news/duality-biotherapeutics-executive-director-of-human-resource","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9606/duality-biotherapeutics-shares/news/duality-biotherapeutics-executive-director-of-human-resource","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09606","HK0000252160.HKD","BK1161","HK0000252152.HKD","LU2543165471.USD","HK0000500386.USD"],"gpt_icon":0},{"id":"1107238891","title":"Hong Kong Stock Movement | DUALITYBIO-B (09606) Surges Over 12% on Rich 2026 Catalysts; Institution Raises Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1107238891","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107238891?lang=en_us&edition=fundamental","pubTime":"2026-01-05 15:08","pubTimestamp":1767596885,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) surged more than 12%. As of writing, the stock was up 12.08% to HK$332.2, with a turnover of HK$321 million. On the news front, Guotai Haitong Securities noted that, based on a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","LU2543165471.USD","HK0000252152.HKD","BK1161","HK0000500386.USD","09606"],"gpt_icon":0},{"id":"1162404111","title":"GTHT Raises DUALITYBIO-B (09606) Target Price to HK$455.56, Maintains Add Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1162404111","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162404111?lang=en_us&edition=fundamental","pubTime":"2026-01-05 09:26","pubTimestamp":1767576398,"startTime":"0","endTime":"0","summary":"GTHT has released a research report stating that, based on the exceptionally smooth progress of DUALITYBIO-B's (09606) pipeline in 2025, it has raised the potential global peak sales expectations for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","BK1564","BK1161","BK1147","HK0000252152.HKD","HK0000252160.HKD","LU2543165471.USD","02611","HK0000500386.USD"],"gpt_icon":0},{"id":"2595796720","title":"Duality Biotherapeutics Inc. held extraordinary general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2595796720","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595796720?lang=en_us&edition=fundamental","pubTime":"2025-12-30 18:42","pubTimestamp":1767091326,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics Inc. held an extraordinary general meeting on December 30, 2025. All proposals set out in the meeting notice were approved by shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 30, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL5h8ph5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2543165471.USD","09606","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0},{"id":"1189000187","title":"Hong Kong Stocks Movement | DUALITYBIO-B (09606) Rises Over 3% in Early Trading as DB-1310 Receives FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1189000187","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189000187?lang=en_us&edition=fundamental","pubTime":"2025-12-19 09:52","pubTimestamp":1766109155,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) surged over 3% in early trading, reaching HK$318 with a turnover of HK$23.3955 million. The company announced that the U.S. Food and Drug Administration (FDA) has granted Fast...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4552","HK0000252152.HKD","LU2543165471.USD","HK0000252160.HKD","HK0000500386.USD","BK1161","09606","BK4566","DB","BK4118","BK4588","BK4585"],"gpt_icon":0},{"id":"1118661640","title":"DUALITYBIO-B (09606) Proposes Adoption of 2025 Share Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1118661640","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118661640?lang=en_us&edition=fundamental","pubTime":"2025-12-14 18:16","pubTimestamp":1765707370,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) announced that on December 13, 2025, its board of directors resolved to propose the adoption of the 2025 Share Scheme, subject to approval by shareholders. The 2025 Share Scheme...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","HK0000500386.USD","BK1161","09606","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0},{"id":"2591681666","title":"Duality Biotherapeutics Inc. Proposes 2025 Share Scheme for Shareholder Approval at Upcoming EGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2591681666","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591681666?lang=en_us&edition=fundamental","pubTime":"2025-12-14 18:06","pubTimestamp":1765706815,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics Inc. has announced a proposal for the adoption of the 2025 Share Scheme, which aims to attract, retain, and reward participants who contribute to the company's long-term growth and success. Shareholders will vote on this proposal at the upcoming extraordinary general meeting. The board recommends voting in favor of the adoption of the 2025 Share Scheme.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251214:nNDL1nVPrZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","HK0000252152.HKD","09606","HK0000252160.HKD","HK0000500386.USD","BK1161"],"gpt_icon":0},{"id":"1173595696","title":"HK Stock Connect Shareholding Changes | December 8","url":"https://stock-news.laohu8.com/highlight/detail?id=1173595696","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173595696?lang=en_us&edition=fundamental","pubTime":"2025-12-08 08:38","pubTimestamp":1765154326,"startTime":"0","endTime":"0","summary":"According to data disclosed on December 5, 2025, the top gainers in HK Stock Connect shareholding ratios were Southern Hong Kong US Tech (03442), Synagistics Holdings (02562), and Jihong Co (02603),...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06865","BK1166","BK1523","BK1161","02498","SG9999004311.SGD","02202","BK1228","01138","SG9999014674.SGD","02587","LU2488822045.USD","01958","BK1100","02333","BK1237","06680","HK0000252152.HKD","BK1175","BK1610","BK1513","BK1587","BK1202","03441","BK1597","01385","BK1511","00694","BK1554","601633","01478","BK1116","BK1507","LU2543165471.USD","BK1617","01709","BK1596","BK1207","03958","BK1589","09606","01341","BK1526","BK1169","LU2148510915.USD","02228","82333","SG9999006597.SGD","BK1196","IE0034224299.USD","BK1535","MCHmain","LU0588546209.SGD","BK1514","BK1197","BK1583","01233","BK1110","BK1518","01317","02828","000002","02631","GWLLY","01282","03678","BK1505","LU1064131003.USD","BK1529","02603","LU0307460666.USD","BK1183","03347","02465","BK1613","BK1096","02208","00638","09863","BK1546","00568","BK1240","BK1258","BK1568","BK1137","BK1561","BK1555","BK1556","BK1205","BK1212","02367","BK1506","03069","BK1141","BK1214","LU1064130708.USD","BK1171","HK0000500386.USD","BK1521","06683","06869","02013","BK1225","02800","02562","00763","02600","BK1607","09885","BK1585","BK1614","02648","BK1504","BK1592","BK1147","BK1576","03442","BK1590","00347","02050","BK1219","02402","00187","02550","HK0000252160.HKD","BK1138","06166","BK1229","BK1539","02582","BK1119","02238","BK1109","03319","BK1163","09858","BK1179","BK1594","BK1149","03759","BK1516","BK1564","BK1542","06682","01858","BK1558"],"gpt_icon":1},{"id":"1127489049","title":"HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127489049","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127489049?lang=en_us&edition=fundamental","pubTime":"2025-12-04 10:26","pubTimestamp":1764815206,"startTime":"0","endTime":"0","summary":"Biotech stocks jumped in Hong Kong. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up about 4%; Zai Lab up over 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"2c8d9a47d2e27ece6292940208c30d20","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","02268","09688","02137","09995","06606","01672","09606","06978","03759","02359","03347","02269"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":-0.0927},{"period":"1month","weight":-0.1548},{"period":"3month","weight":-0.0897},{"period":"6month","weight":-0.3725},{"period":"1year","weight":2.0021},{"period":"ytd","weight":-0.0476}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":-0.0276},{"period":"3month","weight":0.0237},{"period":"6month","weight":-0.0399},{"period":"1year","weight":0.0782},{"period":"ytd","weight":0.0079}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Duality Biotherapeutics Inc is an investment holding company principally engaged in clinical-stage biopharmaceuticals. The Company is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The Company's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The Company's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The Company principally conducts its businesses in domestic and overseas markets.","exchange":"SEHK","name":"DUALITYBIO-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"DUALITYBIO-B(09606),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest DUALITYBIO-B(09606) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"DUALITYBIO-B,09606,DUALITYBIO-B股票,DUALITYBIO-B股票老虎,DUALITYBIO-B股票老虎国际,DUALITYBIO-B行情,DUALITYBIO-B股票行情,DUALITYBIO-B股价,DUALITYBIO-B股市,DUALITYBIO-B股票价格,DUALITYBIO-B股票交易,DUALITYBIO-B股票购买,DUALITYBIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"DUALITYBIO-B(09606),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest DUALITYBIO-B(09606) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}